Riskpilot← Back to searchSign inGet full accessFrederiksstaden Pharma ApS
APSActiveCVR 25630483Frederiksgade 11, st. thPackaging activities · NACE 8292Est. 20002 employees
Revenue 2024
DKK -39K
-51% vs 2023
EBITDA margin
100.0%
+51% vs 2023
Equity ratio
24.1%
Financial strength
Net profit 2024
DKK -51K
+39% vs 2023
| Revenue | DKK -39K | -51% |
| EBITDA | DKK -39K | +51% |
| Net profit | DKK -51K | +39% |
| Total assets | DKK 407K | +24% |
| Equity | DKK 98K | -34% |
| Employees | 2 | — |
Legal name
Frederiksstaden Pharma ApS
CVR number
25630483
Legal form
Anpartsselskab
NACE code
8292 · Packaging activities
Founded
20. september 2000
Share capital
DKK 158.700
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør
Company purpose
Selskabets formål er at drive virksomhed, som udfører kontrakt-/lønarbejde for biotekvirksomheder, lægemiddelproducenter og andre med behov for sterile/partikelfri flydende produkter, samt farmaceutisk konsulentvirksomhed.
Address
Frederiksgade 11, st. th
Phone
+4536495500
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.659 | 3.825 | 3.544 | 2.246 | 964 | 5.639 | 2.163 | 1.352 | 1.225 | 2.044 | -666 | 13 | -80 | -39 |
| Staff expenses | -6.455 | -5.775 | -3.460 | -3.536 | -3.549 | -3.549 | -4.806 | -4.573 | -3.115 | -3.304 | -1.352 | -0 | -0 | -0 |
| EBITDA | 204 | -1.951 | 84 | -1.290 | -2.586 | -2.815 | -4.143 | -3.221 | -1.890 | -1.260 | -2.421 | 13 | -80 | -39 |
| Depreciation & amort. | -133 | -276 | -146 | -205 | -110 | -182 | -118 | -65 | -41 | -60 | -37 | -0 | -0 | -0 |
| EBIT | 71 | -2.227 | -62 | -1.495 | -2.696 | -2.998 | -4.261 | -3.286 | -1.931 | -1.321 | -2.458 | 13 | -80 | -39 |
| Net financials | -16 | -102 | -199 | -194 | -122 | -46 | -11 | -11 | -14 | -806 | 436 | -9 | -4 | -12 |
| Profit before tax | 55 | -2.329 | -262 | -1.690 | -2.818 | -3.044 | -4.272 | -3.297 | -1.945 | -2.144 | -2.022 | 4 | -82 | -51 |
| Tax | 15 | -2 | 25 | -945 | -616 | -664 | 1.968 | -0 | -0 | -371 | -612 | -0 | -0 | -0 |
| Net profit | 40 | -2.327 | -286 | -745 | -2.202 | -2.380 | -6.240 | -3.297 | -1.945 | -1.773 | -1.410 | 4 | -82 | -51 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.817 | 2.473 | 2.312 | 11.413 | 19.349 | 10.197 | 2.317 | 2.352 | 5.948 | 5.316 | 737 | 264 | 328 | 407 |
| Equity | 426 | -1.901 | -2.187 | -2.932 | 9.678 | 7.298 | 1.058 | -2.238 | 3.411 | 1.638 | 227 | 231 | 149 | 98 |
| Long-term debt | 4 | 1.531 | 507 | 621 | 0 | 0 | 0 | 660 | 534 | 1.327 | 0 | 0 | 0 | 0 |
| Short-term debt | 2.391 | 2.843 | 3.973 | 13.363 | 9.671 | 2.899 | 1.258 | 3.930 | 2.003 | 2.352 | 510 | 33 | 180 | 309 |
| Total debt | 2.391 | 4.374 | 4.480 | 14.345 | 9.671 | 2.899 | 1.258 | 4.590 | 2.538 | 3.679 | 510 | 33 | 180 | 309 |
EBITDA margin
-3905900.0%
This company
15.8%
Market median
-24720986% vs market
20122024
Equity ratio
24.1%
This company
38.2%
Market median
-37% vs market
20122024
Return on equity
-51.5%
This company
18.4%
Market median
-380% vs market
20122024
Net profit margin
-5051800.0%
This company
8.1%
Market median
-62368001% vs market
20122024
Asset turnover
-0.10×
This company
1.12×
Market median
-109% vs market
20122024
Debt / equity
3.15×
This company
0.62×
Market median
-408% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-05-01 – 2019-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via CVR / Virk · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via CVR / Virk · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-04-30
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RE Management | Management | 2021 | — | — |
HF Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
JS Management | Management | 2022 | — | — |
SØ Management | Management | 2021 | — | — |
KS Management | Management | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Deputy Chairman | 2016 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2018 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
XGX Pharma ApS | Company | 100.0% | 100.0% | 2022 |
Felumb Holding ApS | Company | 10.0% | 10.0% | 2020 |
CAND.PHARM. POVL M. ASSENS FOND | Company | 33.3% | 33.3% | 2019 |
Kjær Henningsen Holding ApS | Company | 10.0% | 10.0% | 2015 |
HB MEDICAL SCANDINAVIA A/S | Company | 100.0% | 100.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
XGX Pharma ApS
Frederiksstaden Pharma ApS Board members of Frederiksstaden Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Eckersberg | Management | 0 companies |
| Hans Flemming Haagen Jensen | Chief Executive Officer | 0 companies |
| Jens-Nikolaj Schøier | Management | 0 companies |
| Susanne Ølsgaard Felumb | Management | 0 companies |
| Klaus Snej Jensen | Management | 0 companies |
| Søren Wang Petersen | Board of Directors | 0 companies |
| Helle Bøwadt | Deputy Chairman | 0 companies |
| Henrik Grundtvig | Chairman | 0 companies |
| Michael Grundtvig | Board of Directors | 0 companies |
| Lars Karlsmose | Chairman | 0 companies |
| Per Ludvigsen | Chairman | 0 companies |
| Mohammad Sohail Asghar | Board of Directors | 0 companies |
| Lars Grundtvig | Chairman | 0 companies |